Stathmin 2 is a potential treatment target for TDP-43 proteinopathy in amyotrophic lateral sclerosis.

This article discusses the potential of Stathmin 2 (STMN2) as a treatment target for TDP-43 proteinopathy in amyotrophic lateral sclerosis (ALS). TDP-43 is a protein associated with ALS, and its abnormal modifications lead to neurotoxic effects. The study found that the expression of STMN2 was significantly reduced in the presence of TDP-43 depletion, and restoring STMN2 levels rescued neurite outgrowth and axon regeneration. The article suggests that STMN2 is involved in ALS pathology and could be a promising therapeutic approach. However, further research and in vivo examination are needed to confirm the efficacy and safety of targeting STMN2. [Extracted from the article]